Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 6/20 | 0.38 |
| ▸ | NOS1 | P29475 | 5/20 | 0.38 |
| ▸ | NOS3 | P29474 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OTC | P00480 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18594774 | 0.95 | DPP7 (0.43) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL25446446 | 0.95 | DPP7 (0.43) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL8067808 | 0.87 | DPP7 (0.47) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| L-Nil SCHEMBL31540966 | 0.86 | ARG2 (0.50) | DPP7GNAI3GNAO1GNAI1NOS2 | |
| L-Nil SCHEMBL322091 | 0.86 | ARG2 (0.50) | DPP7GNAI3GNAO1GNAI1NOS2 | |
| L-Nil SCHEMBL934874 | 0.86 | ARG2 (0.50) | DPP7GNAI3GNAO1GNAI1NOS2 | |
| SCHEMBL16285441 | 0.85 | KDM4E (0.56) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL21467496 | 0.85 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL5156455 | 0.85 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL8065968 | 0.84 | NOS2 (0.50) | DPP7GNAI3GNAO1GNAI1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012098-B2 | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers | PHARMACIA CORPORATION (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1463495-A4 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1528921-A2 | METHODS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL CONDITIONS | Pharmacia Corporation (US) | 2005-05-11 | — | — | EP | disclosed |
| EP-1505972-A2 | A SELECTIVE INOS INHIBITOR AND A PDE INHIBITOR IN COMBINATION FOR THE TREATMENT OF RESPIRATORY DISEASES | Pharmacia Corporation (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1506040-A2 | SELECTIVE INOS INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES AND CONDITIONS | Pharmacia Corporation (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1463495-A2 | AGENTS AND METHODS FOR TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040127569-A1 | Methods for treatment and prevention of gastrointestinal conditions | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040087653-A1 | Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor | MANNING PAMELA T (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040077639-A1 | Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor | MANNING PAMELA T (US) | 2004-04-22 | — | — | US | disclosed |
| WO-2004012726-A2 | METHODS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL CONDITIONS | PHARMACIA CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003097163-A2 | USING A SELECTIVE INOS INHIBITOR FOR THE TREATMENT OF RESPIRATORY DISEASES AND CONDITIONS | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003097050-A2 | A SELECTIVE INOS INHIBITOR AND A PDE INHIBITOR IN COMBINATION FOR THE TREATMENT OF RESPIRATORY DISEASES | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030013702-A1 | Agents and methods for treatment of cancer | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | disclosed |
| WO-2002076395-A2 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| US-5684008-A | Aminotetrazole derivatives useful as nitric oxide synthase inhibitors | G. D. SEARLE & CO. (US) | 1997-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013702-A1 | Agents and methods for treatment of cancer | FAP, APC, PTGIS | DPP7 2947/4885GNAI3 1372/4885GNAO1 1012/4885 |
| US-20040087653-A1 | Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor | NOS2, NOS1, PDE3A | DPP7 824/4885GNAI3 909/4885GNAO1 814/4885 |
| US-20040077639-A1 | Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor | NOS2, NOS1, NOS3 | DPP7 1396/4885GNAI3 1287/4885GNAO1 1079/4885 |
| US-20040127569-A1 | Methods for treatment and prevention of gastrointestinal conditions | SI, NOS2, NOS3 | DPP7 795/4885GNAI3 1185/4885GNAO1 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.